Skip to content

Study · Randomized controlled trial · n = 97 · 1991

5 results

Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.

Bonneterre J, Kerbrat P, Fargeot P, Metz R, Roche H, Bastit P, Chevrier A, Tubiana-Hulin M, Geyer G, Cappelaere P

European journal of cancer (Oxford, England : 1990)1 Jan 1991Cited by 1 (Europe PMC)

PMID1834115 (opens in a new tab)DOI10.1016/0277-5379(91)90132-w (opens in a new tab)PepBankPUB-01834115
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In breast cancer chemotherapy patients, tetracosactrin and methylprednisolone did not differ in vomiting across the reported assessment periods.

    In plain wordsIn breast cancer chemotherapy patients, tetracosactrin and methylprednisolone did not differ in vomiting.

    Peptide
    Cosyntropin
    Outcome
    No significant changeVomiting including dry heaves
    Study

    n = 97

    Comparator
    Methylprednisolone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    There was no difference either for vomiting (dry heaves were included) or nausea between the two treatments (the analysis was performed on day 1, the worse day of days 2 and 3 and the worse day of days 4 and 5).
    3 context sentences
    Summary · context
    97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study
    Summary · context
    tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration.
    Summary · context
    The tolerability was evaluated using a diary card during 5 days and patients were asked for their preference at the end of the two cycles.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In breast cancer chemotherapy patients, tetracosactrin and methylprednisolone did not differ in nausea across the reported assessment periods.

    In plain wordsIn breast cancer chemotherapy patients, tetracosactrin and methylprednisolone did not differ in nausea.

    Peptide
    Cosyntropin
    Outcome
    No significant changeNausea
    Study

    n = 97

    Comparator
    Methylprednisolone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    There was no difference either for vomiting (dry heaves were included) or nausea between the two treatments (the analysis was performed on day 1, the worse day of days 2 and 3 and the worse day of days 4 and 5).
    3 context sentences
    Summary · context
    97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study
    Summary · context
    tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration.
    Summary · context
    The tolerability was evaluated using a diary card during 5 days and patients were asked for their preference at the end of the two cycles.
  3. 03HumanRandomized controlled trialOther

    In breast cancer chemotherapy patients, slightly more patients preferred tetracosactrin than methylprednisolone.

    In plain wordsIn breast cancer chemotherapy patients, slightly more preferred tetracosactrin than methylprednisolone.

    Peptide
    Cosyntropin
    Outcome
    IncreasePatient preference
    Study

    n = 97

    Comparator
    Methylprednisolone
    Outcome group
    Treatment Preference · Whole body
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Measurements

    P
    0.048
    preference

    Source sentences

    Summary
    However, slightly more patients preferred tetracosactrin (P = 0.048).
    3 context sentences
    Summary · context
    97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study
    Summary · context
    tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration.
    Summary · context
    The tolerability was evaluated using a diary card during 5 days and patients were asked for their preference at the end of the two cycles.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In breast cancer chemotherapy patients, in the first-period analysis, no or mild nausea at day 1 occurred in 49% after tetracosactrin versus 62% after methylprednisolone (not significant).

    In plain wordsIn breast cancer chemotherapy patients, day 1 nausea results did not differ significantly between tetracosactrin and methylprednisolone.

    Peptide
    Cosyntropin
    Outcome
    No significant changeNo or mild nausea on day 1
    Study

    n: not reported in source

    Comparator
    Methylprednisolone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Measurements

    No or mild nausea
    49%
    tetracosactrin
    No or mild nausea
    62%
    methylprednisolone

    Source sentences

    Summary
    At day 1, 49% of the patients experienced no or mild nausea after tetracosactrin and 62% after methylprednisolone (not significant) (first period analysis);
    3 context sentences
    Summary · context
    97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study
    Summary · context
    tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration.
    Summary · context
    The tolerability was evaluated using a diary card during 5 days and patients were asked for their preference at the end of the two cycles.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In breast cancer chemotherapy patients, complete vomiting control occurred in 49% after tetracosactrin versus 53% after methylprednisolone, without significance.

    In plain wordsIn breast cancer chemotherapy patients, day 1 vomiting control did not differ significantly between tetracosactrin and methylprednisolone.

    Peptide
    Cosyntropin
    Outcome
    No significant changeComplete vomiting control on day 1
    Study

    n: not reported in source

    Comparator
    Methylprednisolone
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Measurements

    Complete vomiting control
    49%
    tetracosactrin
    Complete vomiting control
    53%
    methylprednisolone

    Source sentences

    Summary
    a complete control of vomiting (including dry heaves) was observed in 49% of the patients after tetracosactrin and 53% after methylprednisolone (not significant).
    3 context sentences
    Summary · context
    97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study
    Summary · context
    tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration.
    Summary · context
    The tolerability was evaluated using a diary card during 5 days and patients were asked for their preference at the end of the two cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.